Intrinsiqs

Is SAB Biotherapeutics, Inc. overvalued?

SAB Biotherapeutics, Inc. (SABS) — key valuation metrics and fundamentals.

No verdict
Price
$3.29
Fair value
—
Current P/E
—
Normal P/E
—
Market cap
$299.3M
Dividend yield
0.0%
Return on equity
-6.7%
Sector
Healthcare

See the full interactive analysis →

Fair value compares SABS's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 24 Sep 2026.